QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
- 25 June 2018SV NewsDementia Discovery Fund Announces the Appointment of Angus Grant PhD as CEO
- 25 June 2018SV NewsThe Dementia Discovery Fund Raises $350 Million
- 19 June 2018SV NewsDDF Announce Research Collaboration with Immuneering
- 20 February 2018SV NewsDDF welcomes recent FDA guidance which opens new paths for Alzheimer’s treatments
- 2 January 2018SV NewsJLABS - Meet With...Dementia Discovery Fund
- 16 November 2017SV NewsDDF attracts investment from NFL Players Association
- 6 July 2017Portfolio NewsDDF Invests in $20 Million in Series A Funding of Mitoconix Bio to Develop Neurodegenerative Disease Therapies
- 19 June 2017SV NewsDementia Discovery Fund Annual Update
- 1 June 2017Portfolio NewsBicycle Therapeutics Closes £40 Million ($52 Million) in Series B Financing to Advance Clinical Pipeline
- 3 May 2017Portfolio NewsDDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia
- 15 March 2017Portfolio NewsAutifony Therapeutics obtains £1.3 million in funding from Innovate UK and the Dementia Discovery Fund to explore novel approach to treatment of dementia
- 28 February 2017SV NewsDDF Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes